The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …

COVID-19 in complex common variable immunodeficiency patient... : Current Opinion in Allergy
and Clinical Immunology COVID-19 in complex common variable immunodeficiency patients …

Objective Patients with autoimmune inflammatory rheumatic diseases receiving rituximab
(RTX) therapy are at higher risk of poor COVID‐19 outcomes and show substantially …

В середине 2021 года инфекция SARS-CoV-2 (Severe Acute Respiratory coronavirus 2),
вызвавшая пандемию коронавирусной болезни 2019 (coronavirus disease, COVID-19) …

Objective Patients with immune‐mediated inflammatory diseases (IMIDs) receiving B cell–
depleting therapy (BCDT) are among the most vulnerable to severe COVID‐19, as well as …

Objective Patients with immune‐mediated diseases treated with anti‐CD20 monoclonal
antibodies may have worse coronavirus disease 2019 (COVID‐19) outcomes due to …

Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome
coronavirus 2 infections with evidence of active viral replication, due to inability to mount an …

Immunocompromised patients with B-cell deficiencies are at risk for prolonged symptomatic
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We describe 4 …

T cells play a pivotal role in reducing disease severity during SARS-CoV-2 infection and
formation of long-term immune memory. We studied 50 COVID-19 convalescent patients …

Background Patients with multiple sclerosis (MS) on some disease modifying therapies
(DMTs), particularly anti-CD20 and sphingosine-1-phosphate (S1P) modulators, are at …